Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13
Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of vaccination. We evaluated the quantity, quality, and persistence of immunoglobulin G (IgG) and IgA in individuals who received two or three doses of messenger RNA (mRNA) vaccines, compared with previously infected vaccinated individuals. We show that three doses of mRNA vaccine were required to match the humoral responses of preinfected vaccinees. Given the importance of antibody-dependent cell-mediated immunity against viral infections, we also measured the capacity of IgG to recognize spike variants expressed on the cell surface and found that cross-reactivity was also strongly improved by repeated vaccination. Last, we report low levels of CXCL13, a surrogate marker of germinal center activation and formation, in vaccinees both after two and three doses compared with preinfected individuals, providing a potential explanation for the short duration and low quality of Ig induced.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Science advances - 9(2023), 31 vom: 04. Aug., Seite eadg2122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Azarias Da Silva, Marne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 07.08.2023 Date Revised 20.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.adg2122 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36040443X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36040443X | ||
| 003 | DE-627 | ||
| 005 | 20231226082936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.adg2122 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM36040443X | ||
| 035 | |a (NLM)37540749 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Azarias Da Silva, Marne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.08.2023 | ||
| 500 | |a Date Revised 20.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of vaccination. We evaluated the quantity, quality, and persistence of immunoglobulin G (IgG) and IgA in individuals who received two or three doses of messenger RNA (mRNA) vaccines, compared with previously infected vaccinated individuals. We show that three doses of mRNA vaccine were required to match the humoral responses of preinfected vaccinees. Given the importance of antibody-dependent cell-mediated immunity against viral infections, we also measured the capacity of IgG to recognize spike variants expressed on the cell surface and found that cross-reactivity was also strongly improved by repeated vaccination. Last, we report low levels of CXCL13, a surrogate marker of germinal center activation and formation, in vaccinees both after two and three doses compared with preinfected individuals, providing a potential explanation for the short duration and low quality of Ig induced | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a CXCL13 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CXCL13 |2 NLM | |
| 700 | 1 | |a Nioche, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Soudaramourty, Calaiselvy |e verfasserin |4 aut | |
| 700 | 1 | |a Bull-Maurer, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Tiouajni, Mounira |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Dechuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zghidi-Abouzid, Ouafa |e verfasserin |4 aut | |
| 700 | 1 | |a Picard, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Mendes-Frias, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Santa-Cruz, André |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Capela, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrosa, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, António Gil |e verfasserin |4 aut | |
| 700 | 1 | |a Loubet, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Sotto, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Lefrant, Jean-Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Roger, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Claret, Pierre-Géraud |e verfasserin |4 aut | |
| 700 | 1 | |a Duvnjak, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Tu-Anh |e verfasserin |4 aut | |
| 700 | 1 | |a Tokunaga, Kenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestre, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Corbeau, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Mammano, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Estaquier, Jérôme |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 9(2023), 31 vom: 04. Aug., Seite eadg2122 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:31 |g day:04 |g month:08 |g pages:eadg2122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.adg2122 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 31 |b 04 |c 08 |h eadg2122 | ||